文献速递泌尿生殖与妇科肿瘤放疗

经尿道前列腺电切术(TURP)后前列腺立体定向体部放疗(SBRT)的安全性:倾向评分匹配配对分析

Safety of Prostate Stereotactic Body Radiation Therapy after Transurethral Resection of Prostate (TURP): A Propensity Score Matched Pair Analysis.
PubMed 文献 · Pract Radiat Oncol · 2019-04-09

本研究从前瞻性数据库中选取50例曾接受单次TURP、基线排尿功能良好并后续接受SBRT的前列腺癌患者,按糖尿病和放疗体积进行倾向评分匹配至同期非TURP队列,比较两组泌尿生殖毒性。中位随访26个月,两组RTOG急性≥2级、晚期≥2级泌尿生殖毒性、狭窄率和尿失禁率均无显著差异。作者认为SBRT在经仔细选择的TURP后前列腺癌患者中可安全实施。

要点

  • TURP后SBRT组与非TURP组RTOG急性≥2级泌尿生殖毒性分别为6%与8%(P=.45),无显著差异。
  • TURP后SBRT组与非TURP组RTOG晚期≥2级泌尿生殖毒性分别为12%与8%(P=.10),无显著差异。
  • TURP后SBRT组与非TURP组狭窄率分别为6%与4%(P=.64),尿失禁率分别为4%与0%(P=.15),均无显著差异。

核心结论

  • 与非TURP患者相比,TURP后患者接受SBRT的泌尿生殖毒性虽有轻度增加,但仍处于较低水平。
  • 作者认为SBRT可安全用于经仔细选择的TURP后前列腺癌患者。

研究设计与样本

  • 从前瞻性维护的数据库中选取50例曾接受单次TURP、基线排尿功能良好并后续接受SBRT的前列腺癌患者。
  • 将上述患者按糖尿病和放疗体积进行倾向评分匹配至同期接受SBRT的相似非TURP队列。
  • 急性及晚期泌尿生殖毒性采用放射治疗肿瘤学组(RTOG)标准评分,狭窄和尿失禁采用常见不良事件术语标准4.0版评分。

主要发现

  • 全队列中位随访26个月(非TURP组 vs TURP组:30个月 vs 22个月,P=.34)。
  • TURP至SBRT开始的中位间隔为10个月。
  • 非TURP组 vs TURP组RTOG急性≥2级泌尿生殖毒性为8% vs 6%(P=.45),无显著差异。
  • 非TURP组 vs TURP组RTOG晚期≥2级泌尿生殖毒性为8% vs 12%(P=.10),无显著差异。
  • 非TURP组 vs TURP组狭窄率为4% vs 6%(P=.64),尿失禁率为0% vs 4%(P=.15),均无显著差异;晚期毒性发生中位时间非TURP组 vs TURP组为16个月 vs 10个月(P=.12)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the genitourinary (GU) toxicity outcomes in prostate cancer patients treated with stereotactic body radiation therapy (SBRT) who have undergone a prior transurethral resection of prostate (TURP) and compare it to a similar non-TURP cohort. MATERIALS AND METHODS: Fifty prostate cancer patients who had undergone a single TURP, had a good baseline urinary function, and had been subsequently treated with SBRT were chosen from a prospectively maintained database. These were propensity score matched to a similar non-TURP cohort treated during the same period. Matching was done for diabetes mellitus and volume of radiation therapy. Acute GU and late GU toxicity were scored using the Radiation Therapy Oncology Group (RTOG) criteria. Stricture and incontinence were scored using Common Terminology for Common Adverse Events version 4.0. RESULTS: Median follow-up for the entire cohort was 26 months (non-TURP vs TURP, 30 months vs 22 months, P = .34). The median duration between TURP and start of SBRT was 10 months. There was no significant difference between non-TURP versus TURP cohort in terms of RTOG acute GU toxicities grade ≥2 (8% vs 6%, P = .45), RTOG late GU toxicities grade ≥2 (8% vs 12%, P = .10), stricture rates (4% vs 6%, P = .64), and incontinence rates (0% vs 4%, P = .15). The median duration of time to late toxicity was 16 months vs 10 months (P = .12) in non-TURP and TURP cohort, respectively. CONCLUSIONS: Although modestly increased as compared with non-TURP patients, GU toxicities remains low with SBRT in post-TURP patients. SBRT can be safely performed in carefully selected post-TURP prostate cancer patients.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Murthy V, Sinha S, Kannan S, et al. Safety of Prostate Stereotactic Body Radiation Therapy after Transurethral Resection of Prostate (TURP): A Propensity Score Matched Pair Analysis. Pract Radiat Oncol. 2019. PMID: 30978467. doi:10.1016/j.prro.2019.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。